DUXARIL

 

Content  Almitrine bismesylate 30 mg, Raubasine 10 mg.
Description  Each tablet       contains almitrine 30 mg and raubasine 10 mg. It
also contains the       following excipients: Cornstarch, ethylcellulose,
glycerin, hydroxypropyl       methylcellulose, lactose, CI natural red 4,
titanium dioxide, polyethylene       glycol, povidone, colloidal silicon
dioxide, magnesium stearate and talc.
Actions  Antihypoxic drug.
Pharmacology: The actions of       almitrine-raubasine have been demonstrated
in animals, in numerous models       of experimental cerebral hypoxia, as well
as in man, in whom       pharmacoclinical studies have demonstrated the
following:
Increase in the arterial partial pressure       of oxygen (Pa O2 );
Increase in the arterial saturation of oxygen (Sa O2 );
Decrease in the arterial desaturation during effort, a dynamic control      
considered as one of the best techniques currently available to assess the    
efficacy of an antihypoxic molecule;

Increase of the blood level of       2,3-diphosphoglycerate, a factor of oxygen
availability in the arterial       blood;

Increase in the metabolism of the cerebral       tissue as demonstrated, during
the glucose test, by the analysis of the       cortical activity.

The improvement in the blood gas parameters       under almitrine-raubasine is
linked to an improvement of the efficacy of       the alveolar capillary
exchange mechanism without modification of the       ventilatory parameters.

These properties explain the activity of       almitrine-raubasine on the
psychobehavioural disturbances in the elderly.

Pharmacokinetics: Almitrine is       rapidly absorbed and the plasmatic peak is
obtained within 3 hrs after       oral administration. Almitrine and its
metabolites are mainly excreted       through the biliary tract. The
elimination is, thus, mainly through the       faeces. After single
administration, the half-life is between 40-80 hrs;       it is 30 days after
repeated administration. The binding to protein is       high (>99%).

Raubasine is rapidly absorbed, and the       plasmatic peak is obtained 1-2 hrs
after oral administration. After single       administration, the half-life is
between 7-15 hrs; it is 11 hrs after       repeated administration.

Indication    Pathological loss       of cognitive function related to cerebral
aging. Chorioretinal disorders       of ischemic origin. Cochleovestibular
disorders of ischemic origin. Early       & late sequelae of CVA.
Dosage    2 tab daily in 2       divided doses.

Murray Grossan, M.D.
http://www.ent-consult.com